JP2022542804A5 - - Google Patents
Info
- Publication number
- JP2022542804A5 JP2022542804A5 JP2022502218A JP2022502218A JP2022542804A5 JP 2022542804 A5 JP2022542804 A5 JP 2022542804A5 JP 2022502218 A JP2022502218 A JP 2022502218A JP 2022502218 A JP2022502218 A JP 2022502218A JP 2022542804 A5 JP2022542804 A5 JP 2022542804A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- weight
- sodium
- iii
- core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875358P | 2019-07-17 | 2019-07-17 | |
| US62/875,358 | 2019-07-17 | ||
| PCT/US2020/042389 WO2021011808A1 (en) | 2019-07-17 | 2020-07-16 | Cardiac sarcomere inhibitor oral formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542804A JP2022542804A (ja) | 2022-10-07 |
| JP2022542804A5 true JP2022542804A5 (https=) | 2023-07-25 |
| JP7623342B2 JP7623342B2 (ja) | 2025-01-28 |
Family
ID=71995104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502218A Active JP7623342B2 (ja) | 2019-07-17 | 2020-07-16 | 心臓サルコメア阻害剤の経口用製剤 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220265612A1 (https=) |
| EP (1) | EP3999038B1 (https=) |
| JP (1) | JP7623342B2 (https=) |
| KR (1) | KR20220082804A (https=) |
| CN (1) | CN114765954B (https=) |
| AU (1) | AU2020315642B2 (https=) |
| BR (1) | BR112022000495A2 (https=) |
| CA (1) | CA3144972A1 (https=) |
| CL (1) | CL2022000108A1 (https=) |
| DK (1) | DK3999038T3 (https=) |
| ES (1) | ES2974542T3 (https=) |
| FI (1) | FI3999038T3 (https=) |
| HR (1) | HRP20240200T1 (https=) |
| HU (1) | HUE065712T2 (https=) |
| IL (1) | IL289884B2 (https=) |
| LT (1) | LT3999038T (https=) |
| MX (1) | MX2022000708A (https=) |
| PH (1) | PH12022550083A1 (https=) |
| PL (1) | PL3999038T3 (https=) |
| PT (1) | PT3999038T (https=) |
| RS (1) | RS65302B1 (https=) |
| SI (1) | SI3999038T1 (https=) |
| SM (1) | SMT202400107T1 (https=) |
| TW (1) | TW202519217A (https=) |
| WO (1) | WO2021011808A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| PT4370116T (pt) | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| WO2024020468A1 (en) | 2022-07-20 | 2024-01-25 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
| EP4565230A1 (en) | 2022-08-04 | 2025-06-11 | Cytokinetics, Inc. | Methods for treating obstructive hypertrophic cardiomyopathy |
| WO2024179422A1 (zh) * | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
| US20250295639A1 (en) | 2024-03-20 | 2025-09-25 | Cytokinetics, Incorporated | Methods for treating heart diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007027855A2 (en) * | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| NZ598744A (en) * | 2009-09-18 | 2013-11-29 | Sanofi Sa | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
| US20130273096A1 (en) * | 2011-10-05 | 2013-10-17 | Bruce A. Daniels | Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients |
| WO2013112804A1 (en) * | 2012-01-25 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| US9199945B2 (en) * | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| US20170087180A1 (en) * | 2014-06-03 | 2017-03-30 | Sulfagenix, Inc. | Methods and compositions for treating nitric oxide deficiency disorders and related conditions |
| US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| ES2969565T3 (es) * | 2015-09-30 | 2024-12-13 | Max Planck Ges Zur Foerderung Derwissenschaften E V | Derivados heteroarílicos como inhibidores de la sepiapterina reductasa |
| WO2019144041A1 (en) * | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
-
2020
- 2020-07-16 RS RS20240236A patent/RS65302B1/sr unknown
- 2020-07-16 LT LTEPPCT/US2020/042389T patent/LT3999038T/lt unknown
- 2020-07-16 HR HRP20240200TT patent/HRP20240200T1/hr unknown
- 2020-07-16 EP EP20753563.4A patent/EP3999038B1/en active Active
- 2020-07-16 DK DK20753563.4T patent/DK3999038T3/da active
- 2020-07-16 PT PT207535634T patent/PT3999038T/pt unknown
- 2020-07-16 WO PCT/US2020/042389 patent/WO2021011808A1/en not_active Ceased
- 2020-07-16 KR KR1020227003543A patent/KR20220082804A/ko active Pending
- 2020-07-16 FI FIEP20753563.4T patent/FI3999038T3/fi active
- 2020-07-16 CN CN202080062806.7A patent/CN114765954B/zh active Active
- 2020-07-16 ES ES20753563T patent/ES2974542T3/es active Active
- 2020-07-16 BR BR112022000495A patent/BR112022000495A2/pt unknown
- 2020-07-16 HU HUE20753563A patent/HUE065712T2/hu unknown
- 2020-07-16 PH PH1/2022/550083A patent/PH12022550083A1/en unknown
- 2020-07-16 TW TW113138679A patent/TW202519217A/zh unknown
- 2020-07-16 US US17/627,600 patent/US20220265612A1/en active Pending
- 2020-07-16 MX MX2022000708A patent/MX2022000708A/es unknown
- 2020-07-16 AU AU2020315642A patent/AU2020315642B2/en active Active
- 2020-07-16 SM SM20240107T patent/SMT202400107T1/it unknown
- 2020-07-16 SI SI202030397T patent/SI3999038T1/sl unknown
- 2020-07-16 CA CA3144972A patent/CA3144972A1/en active Pending
- 2020-07-16 JP JP2022502218A patent/JP7623342B2/ja active Active
- 2020-07-16 PL PL20753563.4T patent/PL3999038T3/pl unknown
- 2020-07-16 IL IL289884A patent/IL289884B2/en unknown
-
2022
- 2022-01-15 CL CL2022000108A patent/CL2022000108A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022542804A5 (https=) | ||
| FI3999038T3 (fi) | Sydämen sarkomeerin inhibiittorin oraalisia formulaatioita | |
| US11819577B2 (en) | Fixed dose pharmaceutical composition of valsartan and sacubitril | |
| RU2376988C2 (ru) | Фармацевтические композиции замедленного высвобождения, содержащие аплиндор и его производные | |
| US20180360761A1 (en) | Pharmaceutical composition comprising a potent inhibitor of urat1 | |
| US10603282B2 (en) | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine | |
| WO2017208136A1 (en) | Pharmaceutical composition of dapagliflozin co-crystal | |
| US20200368185A1 (en) | Combination formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor | |
| US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
| US20210267908A1 (en) | Pharmaceutical compositions of rivaroxaban | |
| JP2023548855A5 (https=) | ||
| WO2020089761A1 (en) | Pharmaceutical composition comprising of remogliflozin or salt or ester thereof and vildagliptin or salt thereof | |
| WO2022153330A1 (en) | Pharmaceutical compositions comprising acalabrutinib | |
| CA3148035A1 (en) | Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate | |
| RU2022103864A (ru) | Пероральные композиции ингибиторов сердечного саркомера | |
| WO2012050539A1 (en) | Pharmaceutical composition comprising eplerenone | |
| WO2025132571A1 (en) | Immediate release monolayer tablet comprising telmisartan and one or more other antihypertensive agents, method of manufacturing the same, and its use | |
| KR20090107960A (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| JP2021091624A (ja) | ソラフェニブトシル酸塩製剤 | |
| EP2391350A1 (en) | Atazanavir formulations | |
| NZ784934B2 (en) | Cardiac sarcomere inhibitor oral formulations | |
| KR20230096906A (ko) | 페노피브레이트콜린 및 스타틴계 약물을 함유하는 약제학적 복합제제 | |
| WO2024084496A1 (en) | Pharmaceutical compositions comprising acalabrutinib maleate | |
| EP4385502A1 (en) | A pharmaceutical formulation comprising metformin, pioglitazone and a sglt-2 inhibitor | |
| WO2023038600A1 (en) | A capsule formulation comprising macitentan |